Fate Therapeutics Announces Encouraging Dose-Escalation Clinical Data of FATE-NK100 and Provides Regulatory Update on Landmark IND ...
NK100 Shows Clinical Benefit in Treating Advanced Hematologic Malignancies and Solid Tumors Disease Control Shown in All Subjects Re-treated with Second Dose of NK100 No NK100-related Dose Limiting Toxicities Reported Submitted Data to FDA Demonstrating …